This site is intended for health professionals only

New arthritis drug shows promise


Trials with osteoarthritis patients have produced promising results for naproxcinod, a drug in the cyclooxygenase-inhibiting nitric oxide-donator (CINOD) class of anti-inflammatory agents.

Biopharmaceutical company NicOx, which produces the drug, has announced positive top-line results from a 118-patient ambulatory blood-pressure monitoring (ABPM) trial.

The primary ABPM parameter was the mean 24-hour ambulatory systolic blood pressure (SBP), and naproxcinod showed a statistically-significant decrease in SBP of 3.8 mmHg (p=0.011) compared with naproxen.

Raymond Townsend, professor of medicine at the University of Pennsylvania, who advised NicOx on the design and analysis of the study, said: “These impressive results suggest that naproxcinod could represent a valuable treatment alternative for osteoarthritis patients.

Article continues below this sponsored advert
Cogora InRead Image
Explore the latest advances in clinical care at events delivered by renowned experts from CofE

“The hypertensive side effects of COX-2 inhibitors and traditional NSAIDs are a serious medical issue, and there is a clear need for a new drug with no detrimental effect on blood pressure.

“These ABPM data have been obtained in a relevant population of chronically-treated osteoarthritis patients with many cardiovascular risk factors, and clearly show a consistent beneficial effect on blood pressure for naproxcinod across the dose range, in contrast to naproxen.”

NicOx plans to provide further details of the results at a leading cardiology conference next year.

Copyright Press Association 2008


Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine